<DOC>
	<DOC>NCT02159859</DOC>
	<brief_summary>The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.</brief_summary>
	<brief_title>Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients</brief_title>
	<detailed_description>After a hemodialysis session, subject will be administered ertapenem and the amount of ertapenem in the blood will be measured at seven time periods before the initiation of the next hemodialysis session.</detailed_description>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>Men or women age between 18 and 88 at the time of admission to Oakwood Hospital and Medical Center during January 1, 2014 or date of Institutional Review Board (IRB) approval to December 1, 2015 Diagnosed with end stage renal disease and requires hemodialysis three times a week No allergy to Î² lactam medications Existing IV access for parenteral ertapenem infusion Willing for blood draws, at predose, 0.5, 1, 2, 6, 12 hours posthemodialysis and prehemodialysis for the following hemodialysis No evidence of hepatic disease No history of alcoholism or drug abuse within pervious 2 years Not pregnant History of any form of epilepsy, seizure or convulsion Currently taking any forms of valproic acid or divalproex sodium for treatment of any disease states Currently taking probenecid Current Clostridium difficile (C. diff.) infection, defined as 30 days prior to day1 of receiving ertapenem for this study Currently receiving any antimicrobial agents for prophylaxis or treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>88 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>ertapenem</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>requires hemodialysis three times a week</keyword>
</DOC>